BMRN

#761
BioMarin Pharmaceutical Inc. - Common Stock
57.2 9 USD
+8.77%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
57.29
57.29
년간 변동
49.26
66.28
일일 변동
+8.77%
월간 변동
+5.60%
6달 변화
+3.23%
년간 변동율
-2.02%
이전 종가
52.6 7
Open
57.2 9
저가
57.2 9
High
57.2 9
양
194
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 11.07 B
  • Employee 3 221
  • Founded N/A
  • CEO Alexander Hardy
  • Website www.biomarin.com
  • Headquarter Delaware, United States
  • FIGI BBG000CZWZ05
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
40.64
주가매출액비율
3.42

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.

뉴스